N@N

Leland Gershell Upgraded (ASND) to Buy and Held Target at $170 on, Feb 14th, 2022

Leland Gershell of Oppenheimer, Upgraded "Ascendis Pharma A/S" (ASND) to Buy and Held Target at $170 on, Feb 14th, 2022.

Leland has made no other calls on ASND in the last 4 months.

There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 2 agree with Leland's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Yaron Werber of "Cowen & Co." Initiated at Hold and Held Target at $136 on, Thursday, January 6th, 2022
• Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold and Increased Target to $169 on, Wednesday, October 20th, 2021

These are the ratings of the 3 analyists that currently disagree with Leland

---

• Derek Archila of "Wells Fargo" Initiated at Buy and Held Target at $176 on, Wednesday, December 8th, 2021
• Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $190 on, Monday, November 15th, 2021
• Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $179 on, Thursday, November 11th, 2021

Contributing Sources

---